Micro Market Research
+1-888-502-0539
US/CAN Toll Free

You are here :   Home     Healthcare     infertility Treatment     In Vitro Diagnostics    
Real Time Market Research & Industry Analysis - MicroMarketMonitor

North American In Vitro Diagnostics Market

  • Report Code: IN 1001
  • Publish Date: Upcoming
  
Description
Table of Contents
Customer Intelligence
Summary
Inquiry Before Buying Ask for Discount

The North American In Vitro Diagnostics Market is growing due to ongoing developments in analytical laboratory automation; the swift progress in various fields of diagnosis such as point-of-care testing, molecular diagnosis, immunoassays, hematology, flow cytometry, and microbiology; and finally, the geographical market expansion within emerging countries. The most important trend witnessed recently in the IVD industry is the trend of self-testing as opposed to patients visiting hospitals. This is one of the biggest factors responsible for the growth of point-of-care testing, as patients prefer self-testing so as to avoid unnecessary visits to the hospital.

 

In the last five years, the North American IVD industry has witnessed challenging and dynamic market conditions in terms of rising incidences of chronic diseases, increasing awareness of health and fitness, as well as major technological advancements.

 

In 2013, the Americas had the largest market, a 42% share of the Global IVD market, followed by Europe with a 31% share. However, the BRIC countries represent the fastest-growing markets due to the economic growth, the rising number of chronic diseases, and an increasing awareness about the use of IVD tests to control the spread of diseases. Moreover, the economic slowdown, pricing pressures, and high competition in mature countries will compel companies to focus on emerging markets.

 

The major changes in In Vitro Diagnostics have been brought about as a result of the convergence of system engineering, automation, and IT technology. Thus, the new technologies have enabled a better understanding of disease processes. The In Vitro Diagnostics market is expanding, consolidating, and becoming highly competitive with a myriad of opportunities for various new instruments, reagents, calibrators, and other systems.

 

The Centers for Medicare & Medicaid Services (CMS) have estimated that healthcare spending in the U.S. is expected to grow from $2.7 trillion in 2011 to about $4.6 trillion in 2019, at a CAGR of 6.8% for the same period. Similarly, in emerging countries, awareness and an increasing middle-class population, with a more disposable income to spend on healthcare, will be a driving force for the growth of this market.

 

The report “North American In Vitro Diagnostics Market forecast for 2018” analyzes the market by 5 segments such as reagents, instruments, techniques, applications and end-users. The US commanded the largest share in the North American In Vitro Diagnostics market.

 

The report also provides an extensive competitive landscaping of companies operating in this market. The main companies operating in In Vitro Diagnostics Market and extensively covered in this report are Abbott Laboratories, Inc. (U.S.), Roche Diagnostics Limited (Switzerland), Becton, Dickson and Company (U.S.), Siemens Healthcare (Germany), Diagnostica Stago SAS (France), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), ARKRAY, Inc. (Japan), Bio-Rad Laboratories, Inc. (U.S.), DiaSorin S.p.A. (Italy), Sysmex Corporation (Japan), bioMérieux (France), HORIBA, Ltd. (Japan), and Alere, Inc. (U.S.)

 

Segment and country specific company shares, news & deals, M&A, segment specific pipeline products, product approvals and product recalls of the major companies have been detailed.

 

Customization Options:

With the market data, you can also customize the MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standards and deep-dive analysis of the following parameters:

 

Opportunity Analysis

  • Unmet needs, revenue pockets and potential areas for expansion

 

Supplier Evaluation

  • Comprehensive review of key suppliers

 

Lab testing Data

  • Number of IVD tests performed annually in each country tracked till sub-segment level

 

Current and Emerging Products

  • Analysis of current and emerging In Vitro Diagnostics and immunodiagnostic tests
  • Review of current In Vitro Diagnostics instrumentation technologies, and feature comparison of high, medium, and low-volume/POC analyzers

 

Product Analysis

  • Usage pattern (in-depth trend analysis) of products (Segment wise)
  • Product Matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub segment level
  • End-user Adoption rate analysis of the products (Segment wise and Country wise)
  • Comprehensive coverage of Product approvals, Pipeline products and Product recalls

 

Brand/Product Perception Matrix

  • Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virility and tonality of blogs
  • Analysis of overall brand usage and familiarity and brand advocacy distribution (Detractor/Neutral/Familiar)

 

Alternative Products: Impact analysis

MMM’s Healthcare Decision Making Quadrant It is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters like Patient dynamics (Patient pool, epidemiology of disease, preference towards surgeries/alternative therapies) and Macroeconomic indicators (Number of Hospitals and Orthopedic clinics, reimbursement scenario, diagnosis rate, treatment rate and healthcare expenditure)



1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)
2 Executive Summary
3 Market Overview
4 In Vitro Diagnostics-North America, By Segments
4.1 Split By Geography
4.1 In Vitro Diagnostics-USA by Markets
4.1 In Vitro Diagnostics-Canada by Markets
4.1 In Vitro Diagnostics-Mexico by Markets
4.2 Molecular Diagnostics-North America
4.2.1 Molecular Diagnostics-North America, By Endusers
4.2.1.1 Molecular Diagnostics-North America-Hospitals
4.2.1.2 Molecular Diagnostics-North America-Medical & Diagnostic Laboratories
4.2.1.3 Molecular Diagnostics--North America
4.2.2 Molecular Diagnostics-North America, By Technologies
4.2.2.1 Molecular Diagnostics-Transcription-mediated Amplification (TMA)-North America
4.2.2.2 Molecular Diagnostics--North America
4.2.3 Molecular Diagnostics-North America, By Applications
4.2.3.1 Molecular Diagnostics-Genetic Testing-North America
4.2.3.2 Molecular Diagnostics-Microbiology-North America
4.2.3.3 Molecular Diagnostics-Chlamydia trachomatis/ Neisseria gonorrhoeae-North America
4.2.3.4 Molecular Diagnostics-Hepatitis B-North America
4.2.3.5 Molecular Diagnostics--North America
4.2.3.6 Molecular Diagnostics-Breast Cancer-North America
4.2.3.7 Molecular Diagnostics-Human Papillomavirus-North America
4.2.3.8 Molecular Diagnostics-HIV/AIDS-North America
4.2.3.9 Molecular Diagnostics-Tuberculosis-North America
4.2.3.10 Molecular Diagnostics-Hepatitis C-North America
4.2.3.11 Molecular Diagnostics-Methicillin-resistant Staphylococcus aureus (MRSA)-North America
4.2.3.12 Molecular Diagnostics-Colorectal Cancer-North America
4.2.3.13 Molecular Diagnostics-Prostate Cancer-North America
4.2.4 Molecular Diagnostics-North America, By Companies
4.2.4.1 Molecular Diagnostics-North America-Novartis AG
4.2.4.2 Molecular Diagnostics-North America-Gen-Probe Incorporated
4.2.4.3 Molecular Diagnostics-North America-Abbott Diagnostics
4.2.4.4 Molecular Diagnostics-North America-Other Companies
4.2.4.5 Molecular Diagnostics-North America-Abbott Diagnostics
4.2.4.6 Molecular Diagnostics-North America-Other Companies
4.2.4.7 Molecular Diagnostics-North America-Abbott Diagnostics
4.2.4.8 Molecular Diagnostics-North America-Other Companies
4.2.4.9 Molecular Diagnostics-North America-Becton Dickinson & Company
4.2.4.10 Molecular Diagnostics-North America-Cepheid
4.2.4.11 Molecular Diagnostics-North America-BioMérieux
4.2.4.12 Molecular Diagnostics-North America-Siemens AG Healthcare
4.2.5 Molecular Diagnostics-North America, By Geographies
4.2.5.1 Molecular Diagnostics-USA
4.2.5.2 Molecular Diagnostics-Canada
4.2.5.3 Molecular Diagnostics-Mexico
4.2.6 Molecular Diagnostics-North America, By Products
4.2.6.1 Molecular Diagnostics Instruments-North America
4.2.6.2 Molecular Diagnostics Reagents-North America
4.2.6.3 Molecular Diagnostics Services-North America
4.3 Clinical Chemistry-North America
4.3.1 Clinical Chemistry-North America, By Products
4.3.1.1 Clinical Chemistry Services-North America
4.3.1.2 Clinical Chemistry Instruments-North America
4.3.1.3 Clinical Chemistry Reagents-North America
5 In Vitro Diagnostics-North America, By Endusers
5.1 Split By Geography
5.2 In Vitro Diagnostics-USA by Endusers
5.1 In Vitro Diagnostics-Canada by Endusers
5.1 In Vitro Diagnostics-Mexico by Endusers
5.2 In Vitro Diagnostics-North America-Hospitals
5.2.1 In Vitro Diagnostics-North America-Hospitals, By Segments
5.2.1.1 Molecular Diagnostics-North America-Hospitals
5.3 In Vitro Diagnostics-North America-Medical & Diagnostic Laboratories
5.3.1 In Vitro Diagnostics-North America-Medical & Diagnostic Laboratories, By Segments
5.3.1.1 Molecular Diagnostics-North America-Medical & Diagnostic Laboratories
6 In Vitro Diagnostics-North America, By Geographies
6.1 In Vitro Diagnostics-USA
6.1.1 In Vitro Diagnostics-USA, By Segments
6.1.1.1 Molecular Diagnostics-USA
6.2 In Vitro Diagnostics-Canada
6.2.1 In Vitro Diagnostics-Canada, By Segments
6.2.1.1 Molecular Diagnostics-Canada
6.3 In Vitro Diagnostics-Mexico
6.3.1 In Vitro Diagnostics-Mexico, By Segments
6.3.1.1 Molecular Diagnostics-Mexico
7 In Vitro Diagnostics-North America, By Companies
7.1 Competitive landscape
7.2 Split By Geography
7.3 In Vitro Diagnostics-USA by Companies
7.1 In Vitro Diagnostics-Canada by Companies
7.1 In Vitro Diagnostics-Mexico by Companies
7.3 In Vitro Diagnostics-North America-Siemens AG Healthcare
7.3.1 In Vitro Diagnostics-North America-Siemens AG Healthcare, By Segments
7.3.1.1 Molecular Diagnostics-North America-Siemens AG Healthcare
7.4 In Vitro Diagnostics-North America-Johnson & Johnson
7.5 In Vitro Diagnostics-North America-Abbott Laboratories
7.5.1 In Vitro Diagnostics-North America-Abbott Laboratories, By Companies
7.5.1.1 In Vitro Diagnostics-North America-Abbott Diagnostics
7.6 In Vitro Diagnostics-North America-Thermo Fisher Scientific
7.7 In Vitro Diagnostics-North America-Other Companies
7.7.1 In Vitro Diagnostics-North America-Other Companies, By Segments
7.7.1.1 Molecular Diagnostics-North America-Other Companies
7.7.1.2 Molecular Diagnostics-North America-Other Companies
7.7.1.3 Molecular Diagnostics-North America-Other Companies
7.8 In Vitro Diagnostics-North America-F. Hoffmann-La Roche Ltd.
7.8.1 In Vitro Diagnostics-North America-F. Hoffmann-La Roche Ltd., By Companies
7.8.1.1 In Vitro Diagnostics-Roche 454-North America

Please fill in the form below to receive a free copy of the Summary of this Report
















North American In Vitro Diagnostics Market

* Enter the text from the image to the text box :

refresh captcha
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
PRODUCT TITLE PUBLISHED
Brazil Medical Devices Brazil Medical Devices
Peers of Brazil medical devices are Orthopedic Devices, Ophthalmology devices, Endoscopy and Neurology Devices comprising 12.8%, 9.2%, 7.2% and 1.9% respectively of the Global Medical Devices market. It is segmented on basis of endusers and...
Nov 2015
of items
reports | Show
Connect With Us
US/CAN : +1-888-502-0539